HAVE YOUR SAY
PBS listing of second treatment for geographic atrophy (dry AMD). Have your say!
A second new treatment for geographic atrophy (dry AMD) – brand name Izervay®, active ingredient avacincaptad pegol – was registered this December by the Therapeutic Goods Administration (TGA) for people with geographic atrophy, whose vision is threatened by the progression of their condition.
The treatment is not currently listed on the Pharmaceutical Benefits Scheme (PBS). However, the Pharmaceutical Benefits Advisory Committee (PBAC), the advisory body that recommends the listing of medicines on the PBS, will consider avacincaptad pegol for PBS-listed at its meeting in March next year.
If you would like to have your say about the PBS listing of avacincaptad pegol, you can participate in the public consultation.
The PBAC welcomes input from patients, carers, health professionals, consumer groups and members of the public on medicines submitted for PBAC consideration. The PBAC includes these public consultation inputs when considering the clinical and economic evidence presented by the manufacturer of the treatment.
The public consultation online survey for avacincaptad pegol can be accessed here:
If you would like to send a letter via email, you can download a hard copy of the consultation survey and email it to: commentsPBAC@health.gov.au
The deadline for all submissions is 21 January 2026.